drugset / Trial / NCT02651610
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug taxane, will improve the results of the treatment for HER2-negative metastatic breast cancer.
Timeline
- Start
- 2015-12
- Primary completion
- 2017-12
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bavituximab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |